Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Lillian M. Lai et al.|Nature Medicine|2023Cited by 125
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory NeuroblastomaSteven G. DuBois, Araz Marachelian, Yaël P. Mossé et al.|Clinical Cancer Research|2018Cited by 88
Select Bcl-2 antagonism restores chemotherapy sensitivity in high-risk neuroblastomaRachel Tanos, Kelly C. Goldsmith|BMC Cancer|2016Cited by 38
Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastomaJasmine Y. Lee, Kelly C. Goldsmith|Cell Reports Medicine|2023Cited by 16